View clinical trials related to Rejection; Transplant, Liver.
Filter by:The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal. QEL-001 is a product made from a patients own cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it once immune suppression is withdrawn.
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.